Compare FSCO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSCO | NBTX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | FSCO | NBTX |
|---|---|---|
| Price | $6.04 | $21.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 709.7K | 52.9K |
| Earning Date | 01-01-0001 | 09-30-2025 |
| Dividend Yield | ★ 11.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,930,711.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $122.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.08 | $2.76 |
| 52 Week High | $6.00 | $30.35 |
| Indicator | FSCO | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 55.80 |
| Support Level | $6.00 | $20.05 |
| Resistance Level | $6.39 | $21.63 |
| Average True Range (ATR) | 0.16 | 1.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 9.57 | 65.91 |
FS Credit Opportunities Corp is a closed-end management investment company. The Fund's primary investment objective is to generate an attractive total return consisting of a high level of current income and capital appreciation, with a secondary objective of capital preservation. It predominantly invests in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments. The credit instruments in which it invests typically are rated below investment grade by rating agencies or would be rated below investment grade if rated. To achieve its investment objectives, the fund focuses on strategies such as Opportunistic Credit, Special Situations, and Capital Structure Solutions.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.